IP Library Granted Patent US 6,974,794
Granted Patent B1
US 6,974,794 · App. 09/926,167 · Granted Dec 13, 2005

Hemoglobin-antioxidant conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,974,794
App. No.
09/926,167
Granted
Dec 13, 2005
Kind
B1
Abstract

There are provided biocompatible chemical compositions having oxygen transporting capability and comprising oxygen transporting molecules chemically bound to antioxidants, to form compositions capable of protecting a mammalian body from oxidative damage. An example of a composition according to the invention is hemoglobin covalently coupled to a 6-hydroxy chroman carboxylic acid, such as Trolox.

Claims (10)

1. A chemical composition having oxygen transporting capability comprising 2,5,7,8-tetramethyl-2-carboxy-chroman-6-ol (Trolox) conjugate of o-raffinose polymerized hemoglobin (PolyOR-Hb), wherein a ratio of Hemoglobin (Hb) to Trolox during a conjugation is at least 1:1; wherein said composition is prepared by the conjugation of Trolox to o-raffinose polymerized hemoglobin under deoxy or carbonmonoxy condition; and wherein said composition provides greater protection of red blood cells (RBCs) against lysis.

2. The composition of claim 1 , wherein the hemoglobin is intramolecularly cross-linked.

3. The composition of claim 2 , wherein the hemoglobin is intramolecularly cross-linked with oxidized raffinose.

4. The composition of claim 2 , wherein the hemoglobin is intramolecularly and intermolecularly cross-linked.

5. The composition of claim 1 , wherein the hemoglobin is deoxyhemoglobin.

6. The composition of claim 1 , wherein the hemoglobin is carboxyhemoglobin.

7. The composition of claim 1 , wherein the Hb:Trolox ratio is 1:1-1:3.7.

8. The composition of claim 1 , wherein the Trolox is conjugated to PolyOR-Hb under the deoxy condition to prepare said composition with a P50 of 41 mm Hg.

9. The composition of claim 1 , wherein the Trolox is conjugated to PolyOR-Hb under the deoxy condition to prepare said composition with a P50 of 40 mm Hg.

10. The composition of claim 1 , wherein the Trolox is conjugated to PolyOR-Hb under the carbonmonoxy condition to prepare said composition with a P50 of 16 mm Hg.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Feb 16, 2016
From: CATALYST FUND LIMITED PARTNERSHIP II
To: THERAPURE BIOPHARMA INC.
Reel/Frame 037743/0038 →
ASSIGNMENT OF SECURITY INTEREST Recorded Feb 5, 2016
From: THE BANK OF NOVA SCOTIA
To: MDS INC.
Reel/Frame 037731/0875 →
ASSIGNMENT OF SECURITY INTEREST Recorded Feb 5, 2016
From: MDS INC.
To: CATALYST FUND LIMITED PARTNERSHIP II
Reel/Frame 037732/0097 →
SECURITY INTEREST Recorded Nov 23, 2015
From: THERAPURE BIOPHARMA INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037116/0471 →
CHANGE OF NAME Recorded Dec 30, 2008
From: HEMOSOL BIOPHARMA INC.
To: THERAPURE BIOPHARMA INC.
Reel/Frame 022034/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2008
From: HEMOSOL INC.
To: HEMOSOL LP
Reel/Frame 022034/0401 →
VESTING ORDER Recorded Dec 30, 2008
From: HEMOSOL LP
To: 2140304 ONTARIO INC.
Reel/Frame 022034/0536 →
CHANGE OF NAME Recorded Dec 30, 2008
From: 2140304 ONTARIO INC.
To: HEMOSOL BIOPHARMA INC.
Reel/Frame 022034/0592 →